Merck & Co., Inc. Stock Forecast, Price & News

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.

What stocks does MarketBeat like better than Merck & Co., Inc.?

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 22,560,000 shares, a decline of 19.9% from the September 15th total of 28,180,000 shares. Based on an average daily volume of 12,910,000 shares, the days-to-cover ratio is currently 1.7 days.
View Merck & Co., Inc.'s Short Interest.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, October 28th 2021.
View our earnings forecast for Merck & Co., Inc..

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Thursday, October 28th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Wednesday, July, 28th. The company reported $1.31 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.31. The business had revenue of $11.40 billion for the quarter, compared to analysts' expectations of $11.21 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 50.93% and a net margin of 11.48%. During the same quarter in the previous year, the firm earned $1.37 EPS.
View Merck & Co., Inc.'s earnings history.

How has Merck & Co., Inc.'s stock price been impacted by Coronavirus?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRK shares have decreased by 1.2% and is now trading at $78.33.
View which stocks have been most impacted by COVID-19.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, July 27th. Shareholders of record on Wednesday, September 15th will be given a dividend of $0.65 per share on Thursday, October 7th. This represents a $2.60 annualized dividend and a yield of 3.32%. The ex-dividend date of this dividend is Tuesday, September 14th.
View Merck & Co., Inc.'s dividend history.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.32%. Merck & Co., Inc. has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Merck & Co., Inc. is 43.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 41.40% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of $5.470-$5.570 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.150. The company issued revenue guidance of $46.40 billion-$47.40 billion, compared to the consensus revenue estimate of $48.59 billion.

What price target have analysts set for MRK?

11 equities research analysts have issued twelve-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $76.79 to $104.00. On average, they expect Merck & Co., Inc.'s share price to reach $93.31 in the next year. This suggests a possible upside of 19.1% from the stock's current price.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:

• Robert M. Davis, President, Chief Executive Officer & Director
• Caroline A. Litchfield, Chief Financial Officer & Executive Vice President
• Sandy Tremps, Vice President-R&D IT CIO
• Dave Williams, Chief Information & Digital Officer
• Franklin K. Clyburn, Executive VP & President-Human Health

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Merck & Co., Inc.'s key competitors?

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of MRK's competitors.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.03%), Fifth Third Bancorp (0.03%), Manning & Napier Group LLC (0.03%), DNB Asset Management AS (0.03%), Cacti Asset Management LLC (0.03%) and Atalanta Sosnoff Capital LLC (0.02%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, Pensionfund DSM Netherlands, Neville Rodie & Shaw Inc., Fifth Third Bancorp, Sanders Morris Harris LLC, AdvisorNet Financial Inc, and Park National Corp OH.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was acquired by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, Private Advisor Group LLC, Thomasville National Bank, DNB Asset Management AS, Andesa Financial Management Inc., Pacer Advisors Inc., Smith Chas P & Associates PA Cpas, and Capital Investment Advisors LLC.
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $78.33.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. has a market capitalization of $198.28 billion and generates $47.99 billion in revenue each year. The company earns $7.07 billion in net income (profit) each year or $5.94 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 73,500 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

Where are Merck & Co., Inc.'s headquarters?

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at (908) 740-4000 or via email at [email protected].